PDCD1 and non-small cell lung carcinoma: Finally, our data indicated that the development of certain irAEs is associated with improved anti-PD-1 treatment efficacy in patients with NSCLC, which is consistent with earlier studies (Suresh et al. 2018; Teraoka et al. 2017).